Ken Duncan, PhD, discussed the launch of a $50 million initiative focused on developing new drugs for critical pathogens contributing to antimicrobial resistance.
Ken Duncan, PhD
Advertisement
Deputy Director at the Gates Foundation.
Articles by Ken Duncan, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up
2
Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?
3
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
4
